Diaceutics PLC (FRA:7DC)

Germany flag Germany · Delayed Price · Currency is EUR
1.670
+0.050 (3.09%)
Last updated: Jun 3, 2026, 9:55 AM CET
Market Cap142.06M +5.2%
Revenue (ttm)44.06M +19.5%
Net Income111.19K
EPS0.00
Shares Out n/a
PE Ratio1,277.65
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open1.640
Previous Close1.620
Day's Range1.640 - 1.670
52-Week Range1.240 - 2.020
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateMay 26, 2026

About Diaceutics

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using... [Read more]

Industry Commercial Physical and Biological Research
Founded 2005
Employees 213
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7DC

Financial Performance

Financial numbers in GBP Financial Statements

News

Diaceutics Earnings Call Transcript: H2 2025

Revenue grew 20% year-over-year with a return to profitability and a 20% EBITDA margin, driven by expanded recurring revenue, strategic data investments, and growth in enterprise and PMx engagements. The Precision for All strategy broadens the addressable market, supporting future growth and margin expansion.

7 days ago - Transcripts

Diaceutics Annual report: H2 2025

Diaceutics has published its H2 2025 annual report on May 26, 2026.

7 days ago - Filings

Diaceutics Annual report: H2 2025

Diaceutics has published its H2 2025 annual report on May 26, 2026.

7 days ago - Filings

Diaceutics Slides: H2 2025

Diaceutics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on May 26, 2026.

7 days ago - Filings

Diaceutics Slides: Corporate presentation

Diaceutics has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.

8 days ago - Filings

Diaceutics PLC (LSE:DXRX) Q4 2025: Everything You Need to Know Ahead of Earnings

Diaceutics PLC (LSE:DXRX) Q4 2025: Everything You Need to Know Ahead of Earnings

8 days ago - GuruFocus

Diaceutics Earnings release: Q4 2025

Diaceutics released its Q4 2025 earnings on January 15, 2026, summarizing the period's financial results.

4 months ago - Filings

Diaceutics Quarterly report: H1 2025

Diaceutics has published its H1 2025 quarterly earnings report on September 23, 2025.

9 months ago - Filings

Diaceutics Slides: H1 2025

Diaceutics has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 23, 2025.

9 months ago - Filings

Diaceutics Earnings release: Trading Update

Diaceutics released its earnings on July 22, 2025, summarizing the period's financial results.

11 months ago - Filings

Diaceutics price target raised to 195 GBp from 165 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics (DIUXF) to 195 GBp from 165 GBp and keeps an Outperform rating on the shares. Published first on

1 year ago - TheFly

Diaceutics price target raised to 165 GBp from 145 GBp at RBC Capital

RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics to 165 GBp from 145 GBp and keeps an Outperform rating on the shares.

2 years ago - TheFly

Diaceutics initiated with an Outperform at RBC Capital

RBC Capital analyst Natalia Webster initiated coverage of Diaceutics with an Outperform rating and 145 GBp price target. The analyst says the company’s proprietary data and analytics platform enable i...

2 years ago - TheFly